



11-658-C025

Monoclonal Antibody to CD99 Purified Antibody (0.025 mg)

Clone:	3B2/TA8
Isotype:	Mouse IgG2a
Specificity:	The mouse monoclonal antibody 3B2/TA8 recognizes CD99, an approximately 32 kDa sialoglycoprotein expressed on many cell types, with particularly strong expression on Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Within the hematopoietic system, CD99 is expressed on virtually all cell types except granulocytes. HLDA VI.; WS Code T 6T-097, BP 534
Regulatory Status:	RUO
Immunogen:	Human thymocytes
Species Reactivity:	Human
Application:	Flow Cytometry Mass Cytometry
Purity:	> 95% (by SDS-PAGE)
Purification:	Purified by protein-A affinity chromatography
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD99 is a ubiquitous transmembrane type I sialoglycoprotein of a unique and poorly characterized protein family. CD99 is heavily O-glycosylated and was described as a T cell costimulator and strong activator of integrin-mediated actin cytoskeleton assembly, promoting cell adhesion and homotypic aggregation, immediate arrest on an inflamed vascular endothelium, and cell migration through it. Ligation of CD99 under some conditions can lead to apoptosis. Originally CD99 was described as a human thymus leukemia antigen, an Ewing's sarcoma-specific membrane marker, and an adhesion molecule involved in spontaneous rosette formation of T cells with erythrocytes.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies

References:

- *Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
- *Waclavicek M, Majdic O, Stulnig T, Berger M, Sunder-Plassmann R, Zlabinger GJ, Baumruker T, Stöckl J, Ebner C, Knapp W, Pickl WF: CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production. *J Immunol.* 1998 Nov 1;161(9):4671-8.
- *Brémond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K, Breittmayer JP, Gounon P, Gleeson PA, Bernard A, Bernard G: Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction. *Blood.* 2009 Jan 8;113(2):347-57.
- *Pickl WF, Pimentel-Muiños FX, Seed B: Lipid rafts and pseudotyping. *J Virol.* 2001 Aug;75(15):7175-83.
- *Kueng HJ, Leb VM, Haiderer D, Raposo G, They C, Derdak SV, Schmetterer KG, Neunkirchner A, Sillaber C, Seed B, Pickl WF: General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. *J Virol.* 2007 Aug;81(16):8666-76.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz